Strength Training and Resveratrol

NCT06585865 | Recruiting

• 2 other identifiers: YI-2024-02IRB 2024-587
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

The main goal of this study is to find out if supplementing with resveratrol improves skeletal muscle adaptations to strengthening exercise (resistance training or strength training) in adults age 60+, and to determine whether circulating vehicles of inter-organ communication (extracellular vesicles) and their cargo might help explain those responses. The investigators will also examine whether resveratrol supplementation improves blood vessel function and cognitive function (brain health) in response to strength training.

Conditions

Sarcopenia; Anabolic Resistance

Keywords

Resistance training; Aging; Resveratrol; Sarcopenia; Extracellular Vesicles; MicroRNAs

Outcome Measures

Primary Outcomes (5)

• Circulating extracellular vesicle microRNA profile

  Circulating extracellular vesicles will be isolated from plasma and their microRNA cargo will be sequenced.

  During pre-, mid-, and post-testing (each separated by about 6 weeks)

• Muscle torque

  Participants will be instructed to try and straighten their leg, against resistance, as forcefully as possible and maximal torque of the quadriceps assessed using a dynamometer.

  During pre-, mid-, and post-testing (each separated by about 6 weeks)

• Muscle fatigability

  Participants will perform 32 repetitions of knee extensions on a dynamometer and the change in torque from the beginning to the end will be used to indicate fatigability.

  During pre-, mid-, and post-testing (each separated by about 6 weeks)

• Muscle strength

  Participants will perform submaximal testing to assess strength on key exercises included in the strength training protocol.

  During pre-, mid-, and post-testing (each separated by about 6 weeks)

• Appendicular skeletal muscle mass index

  Assessed using dual-energy x-ray absorptiometry (DEXA)

  During pre-, mid-, and post-testing (each separated by about 6 weeks)

Secondary Outcomes (6)

• Waist-to-hip ratio

  During pre-, mid-, and post-testing (each separated by about 6 weeks)

• Vascular function

  During pre-, mid-, and post-testing (each separated by about 6 weeks)

• Cognitive function

  During pre-, mid-, and post-testing (each separated by about 6 weeks)

• Grip strength

  During pre-, mid-, and post-testing (each separated by about 6 weeks)

• Lower body strength/endurance

  During pre-, mid-, and post-testing (each separated by about 6 weeks)

Study Arms (2)

Resveratrol (RSV) group

EXPERIMENTAL

Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.

Behavioral: Resistance training; Dietary Supplement: Resveratrol 500 mg oral once daily.

Placebo

PLACEBO COMPARATOR

Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.

Behavioral: Resistance training; Dietary Supplement: Placebo

Interventions

Resistance training BEHAVIORAL

After pre-testing, participants will perform full-body strength training three times per week for two 6-week blocks. The acute program variables (sets, repetitions, training frequency) will follow a non-linear periodized, progressive design consisting of muti-joint and single-joint exercises. Exercise stress will be varied by using different exercises and loads. The two training blocks will be separated by a mid-intervention testing week, allowing for the study team to monitor participants' progress, communicate progress to participants to promote adherence, and adjust target loads as appropriate for the second half of the intervention. An additional testing week will follow the second 6-week block.

Also known as: Strength training

Placebo; Resveratrol (RSV) group

Resveratrol 500 mg oral once daily. DIETARY_SUPPLEMENT

Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.

Resveratrol (RSV) group

Placebo DIETARY_SUPPLEMENT

Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.

Placebo

Eligibility Criteria

• Age: 60 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 60+
• Minimally active (less than 1 hour of structured exercise/week other than walking)
• No resistance training for the previous 6 months
• Not currently taking resveratrol supplements
• Stable medication, supplement, dietary, and physical activity regimens for the previous 3 months and no plans to change throughout the study period
• Body mass at least 110 lbs

You may not qualify if:

• Medical complications that could increase risk during exercise (e.g., cardiovascular disease, uncontrolled hypertension, type 1 or 2 diabetes, orthopedic contraindication to exercise, kidney disease, etc.)
• Cannabis or nicotine use
• Consume more than 7 alcohol-containing beverages per week

Sponsors & Collaborators

• Texas Tech University: lead
• National Strength and Conditioning Association: collaborator

Study Sites (1)

Department of Kinesiology & Sport Management, Texas Tech University

Lubbock, Texas, 79409, United States

RECRUITING

MeSH Terms

Conditions

Sarcopenia

Interventions

Resistance Training; Resveratrol

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Intervention Hierarchy (Ancestors)

Exercise Therapy; Rehabilitation; Aftercare; Continuity of Patient Care; Patient Care; Therapeutics; Physical Therapy Modalities; Physical Conditioning, Human; Exercise; Motor Activity; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena; Stilbestrols; Stilbenes; Benzylidene Compounds; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polyphenols; Phenols

Study Officials

• Danielle E Levitt, PhD

  Texas Tech University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Danielle E Levitt, PhD

CONTACT

806-834-1830; danielle.levitt@ttu.edu

Jacob A Mota, PhD

CONTACT

806-834-8772; jacob.mota@ttu.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: After pre-testing, participants will be randomized to supplement with resveratrol (500 mg) or placebo for 14 weeks. All participants will complete two 6-week blocks of supervised strength training (full body, 3 days/week); each block will be followed by one week of testing.

Study Record Dates

• First Submitted: September 3, 2024
• First Posted: September 19, 2024
• Study Start: June 13, 2025
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): August 1, 2026
• Last Updated: June 29, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: Dr. Danielle Levitt (PI) will deposit data into the appropriate repositories. Data upload will occur when publications associated with each data set are submitted and made public (where applicable) upon acceptance.
• Access Criteria: Human participants data (except large-scale data sets)- reasonable requests must be submitted to the TTU Dataverse. MicroRNA sequencing data will be available in large-scale output format with no identifiable information (unique code).

Locations

US (1)